Mark C. Liu

6.8k total citations · 1 hit paper
57 papers, 4.8k citations indexed

About

Mark C. Liu is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Immunology and Allergy. According to data from OpenAlex, Mark C. Liu has authored 57 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Physiology, 25 papers in Pulmonary and Respiratory Medicine and 14 papers in Immunology and Allergy. Recurrent topics in Mark C. Liu's work include Asthma and respiratory diseases (39 papers), Respiratory and Cough-Related Research (20 papers) and Allergic Rhinitis and Sensitization (14 papers). Mark C. Liu is often cited by papers focused on Asthma and respiratory diseases (39 papers), Respiratory and Cough-Related Research (20 papers) and Allergic Rhinitis and Sensitization (14 papers). Mark C. Liu collaborates with scholars based in United States, United Kingdom and Canada. Mark C. Liu's co-authors include Steven W. Yancey, Oliver N. Keene, Ian Pavord, Marc Humbert, Lynn E. Katz, Héctor Ortega, Pascal Chanez, Guy Brusselle, J. Mark FitzGerald and Alfredo Chetta and has published in prestigious journals such as New England Journal of Medicine, Annals of Internal Medicine and The Journal of Immunology.

In The Last Decade

Mark C. Liu

56 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

2014 1.6k citations Héctor Ortega, Mark C. Liu et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark C. Liu United States	32	3.3k	2.2k	1.4k	1.1k	715	57	4.8k
Ana R. Sousa United Kingdom	32	4.4k 1.3×	2.6k 1.2×	1.4k 1.0×	1.5k 1.3×	887 1.2×	84	5.9k
John G. Matthews United States	19	3.4k 1.0×	2.1k 0.9×	1.4k 1.0×	1.1k 1.0×	610 0.9×	53	4.3k
Tanya M. Laidlaw United States	34	2.7k 0.8×	1.1k 0.5×	906 0.6×	1.5k 1.3×	702 1.0×	143	4.5k
Andrea Matucci Italy	32	1.1k 0.3×	606 0.3×	1.3k 0.9×	609 0.5×	303 0.4×	114	3.2k
Soo‐Taek Uh South Korea	29	1.4k 0.4×	1.4k 0.6×	678 0.5×	172 0.2×	296 0.4×	152	3.2k
Simonetta Baraldo Italy	35	2.5k 0.8×	3.0k 1.4×	1.1k 0.8×	283 0.3×	268 0.4×	92	4.8k
Graziella Turato Italy	39	3.8k 1.2×	4.8k 2.2×	1.2k 0.9×	264 0.2×	313 0.4×	94	6.9k
Saleh Al‐Muhsen Saudi Arabia	25	1.2k 0.4×	922 0.4×	1.3k 0.9×	231 0.2×	282 0.4×	87	2.9k
Vasiliy V. Polosukhin United States	40	845 0.3×	3.0k 1.4×	1.2k 0.8×	126 0.1×	541 0.8×	94	5.5k
Etsuro Yamaguchi Japan	30	950 0.3×	1.3k 0.6×	475 0.3×	143 0.1×	453 0.6×	125	2.6k

Countries citing papers authored by Mark C. Liu

Since Specialization

Citations

This map shows the geographic impact of Mark C. Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark C. Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark C. Liu more than expected).

Fields of papers citing papers by Mark C. Liu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark C. Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark C. Liu. The network helps show where Mark C. Liu may publish in the future.

Co-authorship network of co-authors of Mark C. Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Mark C. Liu. A scholar is included among the top collaborators of Mark C. Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark C. Liu. Mark C. Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lee, Jason K., S. Pollard, Mark C. Liu, et al.. (2025). Mepolizumab real-world effectiveness in severe asthma with an eosinophilic phenotype and overlapping severe allergic asthma. Annals of Allergy Asthma & Immunology. 135(1). 37–46. 4 indexed citations

Liu, Mark C., Diego Bagnasco, Andrea Matucci, et al.. (2023). Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A Analysis. The Journal of Allergy and Clinical Immunology In Practice. 11(12). 3650–3661.e3. 19 indexed citations

Lemière, Catherine, Camille Taillé, Steven G. Smith, et al.. (2021). Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials. Respiratory Research. 22(1). 184–184. 24 indexed citations

Lugogo, Njira, Mark C. Liu, Ian Pavord, et al.. (2021). Clinical effects of mepolizumab in patients with severe eosinophilic asthma according to background therapy: A meta-analysis. The Journal of Allergy and Clinical Immunology In Practice. 9(9). 3506–3509.e3. 1 indexed citations

Albers, Frank C., Mark C. Liu, Bradley E. Chipps, et al.. (2019). Therapeutic switch from omalizumab to mepolizumab in patients with uncontrolled severe eosinophilic asthma: treatment effect by prior omalizumab treatment duration. Journal of Allergy and Clinical Immunology. 143(2). AB102–AB102. 4 indexed citations

Humbert, Marc, Frank C. Albers, Daniel J. Bratton, et al.. (2019). Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility. Respiratory Medicine. 154. 69–75. 31 indexed citations

Pothoven, Kathryn L., James E. Norton, Lydia Suh, et al.. (2016). Neutrophils are a major source of the epithelial barrier disrupting cytokine oncostatin M in patients with mucosal airways disease. Journal of Allergy and Clinical Immunology. 139(6). 1966–1978.e9. 115 indexed citations

Ortega, Héctor, Mark C. Liu, Ian Pavord, et al.. (2014). Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. New England Journal of Medicine. 371(13). 1198–1207. 1591 indexed citations breakdown →

Chen, Edward S., Zhimin Song, Matthew H. Willett, et al.. (2009). Serum Amyloid A Regulates Granulomatous Inflammation in Sarcoidosis through Toll-like Receptor-2. American Journal of Respiratory and Critical Care Medicine. 181(4). 360–373. 173 indexed citations

10.

Kato, Atsushi, et al.. (2009). Local release of B cell–activating factor of the TNF family after segmental allergen challenge of allergic subjects. Journal of Allergy and Clinical Immunology. 123(2). 369–375.e2. 34 indexed citations

11.

Schroeder, John T., et al.. (2005). TLR9- and FcεRI-Mediated Responses Oppose One Another in Plasmacytoid Dendritic Cells by Down-Regulating Receptor Expression. The Journal of Immunology. 175(9). 5724–5731. 126 indexed citations

12.

Sanders, Scherer P., et al.. (2004). Role of nasal nitric oxide in the resolution of experimental rhinovirus infection. Journal of Allergy and Clinical Immunology. 113(4). 697–702. 76 indexed citations

13.

Bochner, Bruce S., et al.. (2003). Release of both CCR4-active and CXCR3-active chemokines during human allergic pulmonary late-phase reactions. Journal of Allergy and Clinical Immunology. 112(5). 930–934. 111 indexed citations

14.

Bochner, Bruce S., et al.. (2002). Expression of Activation Markers on Alveolar Macrophages in Allergic Asthmatics after Endobronchial or Whole-Lung Allergen Challenge. Clinical Immunology. 104(1). 77–85. 41 indexed citations

15.

Taylor, Marcia L., Paul W. Noble, Barbara White, et al.. (2000). Extensive Surface Phenotyping of Alveolar Macrophages in Interstitial Lung Disease. Clinical Immunology. 94(1). 33–41. 37 indexed citations

16.

Peebles, R. Stokes, Mark C. Liu, Lawrence M. Lichtenstein, & Robert G. Hamilton. (1995). IgA, IgG and IgM quantification in bronchoalveolar lavage fluids from allergic rhinitics, allergic asthmatics, and normal subjects by monoclonal antibody-based immunoenzymetric assays. Journal of Immunological Methods. 179(1). 77–86. 44 indexed citations

17.

Liu, Mark C., et al.. (1994). Identification of IgE-Bearing Cells in the Late-Phase Response to Antigen in the Lung as Basophils. American Journal of Respiratory Cell and Molecular Biology. 10(4). 384–390. 119 indexed citations

18.

Liu, Mark C., et al.. (1994). Application of a flow cytometric method using autofluorescence and a tandem fluorescent dye to analyze human alveolar macrophage surface markers. Journal of Immunological Methods. 172(1). 17–24. 24 indexed citations

19.

Krishnaswamy, Guha, Mark C. Liu, Song‐Nan Su, et al.. (1993). Analysis of Cytokine Transcripts in the Bronchoalveolar Lavage Cells of Patients with Asthma. American Journal of Respiratory Cell and Molecular Biology. 9(3). 279–286. 81 indexed citations

20.

Wagner, Elizabeth M., Eugene R. Bleecker, Solbert Permutt, & Mark C. Liu. (1992). Peripheral Airways Resistance in Smokers. American Review of Respiratory Disease. 146(1). 92–95. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact